» Articles » PMID: 34941736

Botulinum Toxin Therapy in Writer's Cramp and Musician's Dystonia

Overview
Journal Toxins (Basel)
Publisher MDPI
Specialty Toxicology
Date 2021 Dec 23
PMID 34941736
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Task-specific focal dystonia is characterized by muscle contraction(s) during a specific task, resulting in abnormal postures or movements. Specifically, writer's cramp involves the upper extremity during the act of writing. Musician's dystonia has a highly variable presentation, and thus makes therapeutic options more limited. Treatments include oral pharmacologic agents, neuromodulation, surgery and, most often, botulinum toxin (BoNT) injection. Selection of target muscles for toxin injection continues to be an area of active research for these task-specific movements. We present a review of the literature selected from a predefined search of the and ClinicalTrials.gov databases. We include six controlled studies of botulinum toxin for the management of writer's cramp and focal task-specific dystonia (FTSD), including musician's dystonia. Overall, 139 patients were included across all studies, with 99 individuals injected for writer's cramp and the remaining 40 individuals with FTSD. The age range of all patients was 18-80 years old. We included studies that utilized only the BoNT-A serotype. These studies utilized various severity scales to quantify response to toxin injection, with ratings of instrument or pen control included as subjective ratings. Of the included 139 patients in this review, pooled data for toxin response show that 73% of patients who received the drug demonstrated improvement. Specific techniques for muscle localization and targeting were difficult to study as variable methods were employed. This remains an area of ongoing exploration.

Citing Articles

Patient Burden in Dystonia Diagnosis and Botulinum Toxin Treatment: A Nationwide Survey in Turkey.

Yilmaz R, Oksuz N, Ceylan M, Samanci B, Acarer A, Durmaz Celik N Brain Behav. 2025; 15(3):e70325.

PMID: 40021839 PMC: 11870789. DOI: 10.1002/brb3.70325.


Bibliometric analysis of research developments in oral and maxillofacial neuralgia from 2004 to 2023.

Cai Y, Liu K, Xiang J, Zheng H, Zhang D, Wang Y Medicine (Baltimore). 2024; 103(50):e40715.

PMID: 39686494 PMC: 11651469. DOI: 10.1097/MD.0000000000040715.


Incobotulinum Toxin-A in Professional Musicians with Focal Task-Specific Dystonia: A Double Blind, Placebo Controlled, Cross-Over Study.

Frucht S, George M, Pantelyat A, Altenmueller E, Nmashie A, Jiao J Tremor Other Hyperkinet Mov (N Y). 2024; 14:32.

PMID: 38948014 PMC: 11212776. DOI: 10.5334/tohm.903.


Clinical neurophysiology in the treatment of movement disorders: IFCN handbook chapter.

Lefaucheur J, Moro E, Shirota Y, Ugawa Y, Grippe T, Chen R Clin Neurophysiol. 2024; 164:57-99.

PMID: 38852434 PMC: 11418354. DOI: 10.1016/j.clinph.2024.05.007.


Genetic Update and Treatment for Dystonia.

Koptielow J, Szylak E, Szewczyk-Roszczenko O, Roszczenko P, Kochanowicz J, Kulakowska A Int J Mol Sci. 2024; 25(7).

PMID: 38612382 PMC: 11011602. DOI: 10.3390/ijms25073571.


References
1.
Dressler D, Adib Saberi F, Rosales R . Botulinum toxin therapy of dystonia. J Neural Transm (Vienna). 2020; 128(4):531-537. PMC: 8099791. DOI: 10.1007/s00702-020-02266-z. View

2.
Chen R, Hallett M . Focal dystonia and repetitive motion disorders. Clin Orthop Relat Res. 1998; (351):102-6. View

3.
Lungu C, Karp B, Alter K, Zolbrod R, Hallett M . Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more. Mov Disord. 2011; 26(4):750-3. PMC: 3081109. DOI: 10.1002/mds.23504. View

4.
Jankovic J . Treatment of dystonia. Lancet Neurol. 2006; 5(10):864-72. DOI: 10.1016/S1474-4422(06)70574-9. View

5.
Jabusch H, Zschucke D, Schmidt A, Schuele S, Altenmuller E . Focal dystonia in musicians: treatment strategies and long-term outcome in 144 patients. Mov Disord. 2005; 20(12):1623-6. DOI: 10.1002/mds.20631. View